Targeting and Regulation of the HER-2/neu Oncogene Promoter with Bis-Peptide Nucleic Acids
Amy Ziemba, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yulia Krotova-Khan(University of Arizona), Lenka Stankova(Arizona Oncology), Zhanna V. Zhilina(University of Arizona)
Cited by 10
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k